T he role of the renin-angiotensin (Ang) II system, particularly of Ang II, holds high interest in the areas of cardiovascular and renal physiology and pathology. Of most interest, after the discovery of the beneficial effects of Ang II-converting enzyme (ACE) inhibitors in hypertension and cardiovascular and renal disease, are Ang II's nonhemodynamic effects 1,2 rather than its better-known hemodynamic effect as a vasopeptide. The L-arginine/nitric oxide (NO) pathway, particularly NO as an endothelial-derived relaxing factor, has also been an area of keen interest. [3] [4] [5] [6] The interactions of and balance between Ang II and NO are of key importance in cardiovascular and renal injury and are the focus of this review. Indeed, the presence or the relative bioavailability of either one can make it either injurious or protective of target organs ( Figure 1 ).
Research shows general agreement that functionally complete local renin-angiotensin systems are operative within organs/tissues. [7] [8] [9] The systems act in both autocrine and paracrine fashion, 7, 8 potentially accounting for the local actions of Ang II and NO; angiotensin II and NO interact at the level of the endothelium, which is where they undergo the final step of synthesis as well as at the level of vascular smooth muscle cells, mesangial cells, and matrix. The endothelial cells contain ACE, which converts Ang I to Ang II. NO has been shown to downregulate the synthesis of ACE 10 in the endothelium, as well as Ang II type 1 receptors (AT 1 ) in vascular smooth muscle cells, thus having the potential to decrease Ang II production and action. 11, 12 NO is synthesized in the endothelium by a constitutive endothelial NO synthetase (eNOS), part of the NOS isoforms family. 3, 5 eNOS is calcium-and calmodulin-dependent 3, 5 and can be activated by neurohumoral substances such as acetylcholine, substance P, bradykinin, and adenosine diphosphate as well as by such mechanical stimuli physical forces as shear stress and cyclic strain. Under physiological conditions such as exercise, eNOS is upregulated, leading to vasodilation and increased blood flow to the organs. 13, 14 NO, which has a short half-life, is rapidly inactivated either by superoxide anions (O 2 Ϫ ) or by binding to hemoglobin 5 after release. Thus, increased levels of O 2 Ϫ , as they occur in pathological conditions, may dramatically shorten the bioactivity of NO and/or transform it into a toxic metabolite. 15 NO actions can be inhibited by NOS inhibitors, whereas Ang II, because it combines with receptors to exert its actions, can be inhibited by Ang II receptor blockers. 1 ACE inhibitors not only decrease Ang II synthesis but prevent the degradation of bradykinin, one of the most important physiological molecules involved in the release of NO. 16 -18 The main subtypes of Ang II receptors are AT 1 and AT 2 . 19,20 AT 1 mediates the vasoconstrictor effect of Ang II and mediates the Ang II-induced growth in cardiovascular and renal tissue. 17 NO can downregulate AT 1 receptors in vascular tissue 11 and the adrenal gland 12 and mitigate the actions of Ang II. 21 AT 2 actions are less well understood, although it is known that in adult animals, they may upregulate in response to injury. AT 2 receptors have been associated with the synthesis and/or the release of both prostaglandins and NO. 22, 23 
Interaction of Ang II and NO in the Regulation of Vascular Tone
Hypertension involves 3 major factors: abnormal vascular tone, abnormalities in volume and salt regulation, and vessel wall remodeling. Both NO and Ang II are important players in these pathogenetic mechanisms.
Ang II is a potent vasoconstrictor with growth-promoting properties. In the kidney, this vasoconstrictor effect is more pronounced in the efferent than the afferent glomerular arterioles and leads to an increase in glomerular capillary pressure. 24 -26 Various factors may cause the differential intrarenal vasoconstrictor response to Ang II: smaller efferent arteriolar diameter, 27 maintenance of an afferent vasodilatory tone by NO, 24, 28, 29 and activation of AT 2 receptors in the afferent arterioles, resulting in vasodilation through the cytochrome P-450 -dependent pathway. 30 NO is a vasodilator with antigrowth and antithrombogenic effects that plays a role in maintaining vascular integrity and preventing end-organ damage. Its vasodilatory effect is mainly on the afferent arteriole in the cortical nephrons, but it can affect both afferent and efferent arterioles in juxtamedullary nephrons. 31, 32 AT 1 receptor blockade can abolish the vasoconstrictor effect of NOS inhibition on cortical blood flow but has minor effects on medullary blood flow, 33 which suggests that NO may be a more effective modulator of Ang II-mediated vasoconstriction in cortical than in medullary nephrons. 33 NO production is continuous, imparting a constant vasodilatory effect 24 and helping maintain resting vascular tone and normal blood pressure. Ang II production is not as constant, however, and its main physiological role is to increase vascular tone in response to decreased blood volume and/or flow. Its contribution to the steady state of vascular tone in the stable, homeostatic individual is unclear. 24, 34 The kidney's inability to adequately excrete salt is considered to be a major pathogenetic component in hypertension. NO may play a role in salt excretion by directly decreasing tubular sodium reabsorption or indirectly through modulation of renal medullary blood flow. 15,34 -36 Ang II, however, has antinatriuretic properties because of its effects on the renal tubules and renal blood flow plus the feedback regulation of renin release from the macula densa. 25, 34 In people with essential hypertension, impairment of NOmediated endothelium-dependent relaxation occurs. 37, 38 At times, the impairment precedes the hypertension, which has been found to occur in some normotensive blacks 39 and normotensive offspring of hypertensives. 40 Many normotensive offspring of patients with premature myocardial infarction manifest abnormal endothelium-dependent relaxation and increased intima-media thickness in the carotid arteries. 41 Development of hypertension has been documented in animals with long-term blockade of NO synthesis or knockout of the NOS gene, whereas hypotension has been found in mice that overexpress the NOS gene. 42, 43 Local administration of the NOS inhibitor N G -monomethyl-L-arginine into the brachial artery of humans produces a dose-dependent fall in forearm flow, 44 which suggests that NO also participates in the regulation of vascular tone in humans.
The synthesis or release of such vasoactive agents as endothelin-1 (ET-1) and Ang II are likely modulated by the effects of NO, as shown by increasing evidence. 45, 46 Interaction between NO and ET-1 appears to be more important under pathological than physiological conditions, because ET-1 synthesis is upregulated by Ang II and downregulated by NO.
The development and/or maintenance of both hypertension and the abnormal vascular remodeling that occurs in such circumstances as atherosclerosis and after myocardial injury 47, 48 is probably due in part to a loss of NO and, more important, to an imbalance among Ang II, NO, and O 2 Ϫ production. 45, 47, 49 
NO-Ang II in Cardiovascular and Renal Injury
Vascular remodeling is a dynamic process of adaptation of the vascular beds to hypertension caused increases in hemodynamic workload. 47 All cellular components participate in the process. In the heart, remodeling results in myocyte hypertrophy and increased extracellular matrix; 47 in vessels, it is characterized by an increased media/lumen ratio; and in the glomerulus, it results in an increase in size and number of mesangial cells and/or the amount of mesangial matrix. 45, 50, 51 These adaptive changes end up being maladaptive in many patients, leading to left ventricular hypertrophy (LVH) and heart failure, ischemia of vascular territories, and renal failure. 52 Ang II affects growth-related processes directly as well as indirectly by means of synthesis of growth factors such as platelet-derived growth factor and transforming growth factor-␤ (TGF-␤). 47, 51 In addition, it promotes synthesis of ET-1, which is in itself a vasoconstrictor and facilitator of vascular smooth muscle cell and mesangial cell growth. 46, 53 NO, however, downregulates TGF-␤ and has been shown to be a powerful endogenous inhibitor of growth-related responses in vascular smooth muscle cells, mesangial cells, and extracellular matrix. 26 In addition, platelet aggregation and the expression of adhesion molecules are inhibited by NO. 6, 26 These actions of NO have been confirmed in in vivo studies in mice that are genetically deficient in endothelial NOS and subjected to hemodynamic injury. 48, 54, 55 Finally, recent studies have shown that NO downregulates synthesis of both ACE 10 and AT 1 receptors 11 and inhibits the synthesis of ET-1. 56 Experimentally, inhibition of renal NO synthesis results in increased intrarenal synthesis of Ang II. 57 Clinically, blockade of the AT 1 receptor normalizes NO-mediated vascular relaxations in patients with atherosclerosis. 58 A new mechanism involved in the countervailing interaction between NO and Ang II was elucidated recently, namely the activation of NADH/NADPH oxidases that lead to the production of O 2 Ϫ . Ang II-driven O 2 Ϫ production has been identified in vascular smooth muscle cells, 19 mesangial cells, 59 and aortic adventitial fibroblasts. 60 Extracellularly, O 2 Ϫ inactivates NO; whereas intracellularly, it activates MAP kinases and leads to vascular smooth muscle and mesangial cell hypertrophy. 15, 19, 59 The pathogenesis of hypertensive end-organ injury is affected by both an NO deficit and an Ang II increase. 19 Most studies suggest that end-organ damage in hypertension is diffuse and affects organs to different degrees within individual patients. 52 The endothelial response to hypertension is to organize a complex local environment that includes upregulation of NO and inhibition of the effects of Ang II. It is through this endothelial function that end organs may be spared from the effects of hypertension. 13, 15, 61, 62 In experimental models of hypertension, spontaneously hypertensive rats (SHR) show increased production of renal, aortic, and cardiac NO, whereas Dahl salt-sensitive rats (DS) show decreased NO production. DS show 5 times more proteinuria than SHR and 9 times more glomerular injury at similar blood pressure; 62,63 they also show more aortic hypertrophy and LVH. 62 These results suggest that in response to hypertension, DS have a paradoxical decrease in NO production that ultimately promotes cardiovascular and renal injury. 62 It is reasonable to conclude that the cause of end-organ dysfunction in hypertensive individuals is multifactorial and that both Ang II and NO appear to play a pivotal but not exclusive role. 26 Decreased vascular NO bioactivity that results from endothelial dysfunction may promote abnormal end-organ vascular remodeling through either absolute or relative changes in the level of activity of NO compared with Ang II. 26, 48 
NO-Ang II in Diabetes and in Insulin Resistance
Hypertensive patients as well as their first-degree relatives commonly show abnormalities of insulin, glucose, and lipoprotein metabolism. 64 In many patients, insulin resistance, manifested by a defect in the ability of insulin to stimulate the metabolism of glucose by muscle and its storage as glycogen, is the hallmark of this metabolic syndrome. It is important to realize, however, that although insulin resistance and hyperinsulinemia are common in hypertensive patients, hypertension does not occur in all patients with hyperinsulinemia.
Insulin resistance and hyperinsulinemia are more severe and more closely associated with hypertension in obese than in nonobese patients. 64 The prevalence of microalbuminuria is increased in hypertensive patients with insulin resistance; microalbuminuria as well as insulin resistance and hyperinsulinemia have been associated with an increased risk for atherosclerotic cardiovascular disease. 64 Steinberg et al 65 demonstrated that insulin enhances the release of endothelium-derived NO, and Baron et al 66 demonstrated that insulin-resistant states including obesity, hypertension, and type 2 diabetes mellitus exhibit blunted insulin-mediated vasodilation and impaired endotheliumdependent vasodilation. These investigators suggested that endothelial dysfunction is an integral component of the syndrome of insulin resistance, independent of hyperglycemia; they further suggested that the endothelial dysfunction worsens insulin resistance and predisposes individuals to macrovascular disease.
NO-Ang II in Salt Sensitivity
Bigazzi et al 64 reported that salt-sensitive patients with essential hypertension are more likely to manifest hyperinsulinemia, hyperlipidemia, and microalbuminuria. In this context, therefore, salt sensitivity can be a marker for increased cardiovascular risk in patients with essential hypertension.
Findings by Reaven et al 67 demonstrated remarkable similarity between DS and salt-sensitive humans: compared with control Sprague-Dawley rats, DS manifested a defect in insulin-stimulated glucose uptake by isolated adipocytes. These metabolic changes do not depend on DS eating a high-salt diet and do not vary as a function of salt intake, which suggests that in the rats, as in salt-sensitive humans, 68 susceptibility to the development of endothelial dysfunction and end-organ disease is part of the cluster of abnormalities that predispose to hypertension. 69 Similar to the observations in SHR, 62 groups of patients with severe hypertension have been identified who are not salt sensitive, have minimal LVH, no renal injury, and normal endothelial function. 70 The association between microalbuminuria and the progression of diabetic nephropathy has been clearly established in patients with type 1 diabetes mellitus. However, recent studies from several laboratories have established that microalbuminuria is a marker of cardiovascular morbidity in nondiabetic patients with essential hypertension as well as in patients with type 2 diabetes mellitus. 71 Salt-sensitive hypertensive patients have a greater incidence of microalbuminuria; 64, 71, 72 this has led investigators to suggest that microalbuminuria may be a useful predictor of salt sensitivity and renal hemodynamic abnormalities in patients with essential hypertension. 73 In atherosclerosis, there is upregulation of vascular ACE and AT 1 receptors and decreased bioactivity of NO. Clinically, AT 1 receptor blockade normalizes endothelium-dependent relaxations mediated by NO in patients with atherosclerosis. 58 Statins have been shown to upregulate eNOS and decrease ET-1 synthesis. 74 The association between endothelial dysfunction, dysregulation of NOS activity, end-organ damage, and salt sensitivity in hypertension is intriguing. Salt-sensitive hypertension has been linked to a decrease in renal NO production, inappropriate activation of the renin-angiotensin system, or both. 71, 72 However, a causality relationship between salt sensitivity and NO deficiency has not yet been clearly identified. 71 Heimann et al 75 reported a higher incidence of left ventricular mass in salt-sensitive hypertensive patients than in salt-resistant hypertensive patients. More recently, in a study of 350 Japanese patients with essential hypertension, Morimoto et al 76 demonstrated that patients who were saltsensitive more often had LVH and experienced more cardiovascular events than the non-salt-sensitive hypertensive patients.
Several studies have shown an association between endothelial function and vascular compliance and suggest that endothelium dependent vascular relaxation (EDR) mediated by NO contribute to the maintenance of vascular compliance. 77 In the aorta, a reduction in vascular compliance promotes LVH because of increased impedance to left ventricular function. 77 It has been reported that salt-sensitive hypertensive patients manifest impaired EDRs that are mediated by NO. 68 It has been suggested that impaired vascular relaxation precedes hypertension in some populations of blacks and that it further deteriorates with age and after the development of hypertension. 78 Similar observations have been made in Italy in children of hypertensives. 40 Impaired NOS activity in salt-sensitive experimental models of hypertension has been demonstrated. 62, 79 In hypertensive humans, independent of the effects of salt on blood pressure, salt sensitivity may be a marker for susceptibility to cardiovascular and renovascular injury. 64, 72 It is interesting to note that aging as well as diabetes are characterized by increased prevalence of hypertension, salt sensitivity, and decreased EDR-mediated by NO. 68, 80 Hence, it is tempting to speculate that in hypertension, salt sensitivity, whether primary (ie, certain populations in the United States and Japan) 76, 78 or secondary (ie, aging, type II diabetes mellitus), 81 is a marker of increased cardiovascular and renal risk that is linked to a decreased bioactivity of NO (Figure 2 ).
NO-Ang II and the Kidney
NO synthesis inhibition and Ang II stimulation are quite similar in terms of regulation of vascular tone and vascular pathology. It remains unclear the extent to which the vasoconstrictor response to NO blockade results from withdrawal of an active NO vasodilatory stimulus and how closely related this response is to amplification of underlying vasoconstrictor systems. 10, 82, 83 Ang II blockade has not been found to have an effect on the renovasoconstrictor response to acute NO inhibition in the conscious unstressed rat. 84, 85 In the conscious rat and dog, however, infusion of Ang II given alone at a dose that has little effect on renovascular resistance causes massive renal vasoconstriction when the NO system is also acutely inhibited. 86 Thus, the renal vasoconstriction produced by acute NO blockade does not require the participation of the Ang II system. However, when Ang II levels are sufficiently high to affect renovascular tone, NO is important in maintaining renal perfusion. 6, 24 Intrarenal inhibition of NO causes an increase in afferent arteriolar resistance and a decrease in the ultrafiltration coefficient. 87 This is, at least in part, the result of the unopposed action of Ang II. 32, 88 However, the glomerular capillary pressure does not change unless the systemic administration of NOS inhibitors results in a significant increase in systemic arterial blood pressure. 32, 88 Selective inhibition of NO synthesis in renal medullary interstitium decreases papillary blood flow and diminishes urinary sodium excretion without altering GFR or systemic blood pressure. 89, 90 The situation with chronic NOS inhibition is different. Hypertension caused by chronic inhibition is not entirely NO-dependent. 91 Moreover, the rescue administration of L-arginine had no effect in a chronic model of hypertension in which NO had been inhibited for 5 to 6 weeks. 91 This chronic NO inhibition is accompanied by increased intrarenal Ang II synthesis and upregulation of TGF-␤ and results in glomerular and tubulointerstitial injury, 62 as well as coronary vas- cular remodeling, LVH, and hypertension. 6, 61 Studies that compared endothelial NOS knockout mice to wild mice showed that in the former mice, a more marked increase in vessel wall thickness develops because of vascular smooth muscle hyperplasia in response to hemodynamically mediated vascular injury. 48 Pulmonary artery hypertrophy in response to hypoxia is also more marked in these mice. 54 Hayakawa and Raij 62 suggested that deficiency in NO synthesis conditions the severity of vascular and ventricular hypertrophy in response to hemodynamic changes in genetic models of hypertension. This led to the conclusion that although acute inhibition of NO leads to hypertension, once the chronic phase is established, NO deficiency is not the sole mechanism for the maintenance of hypertension and target organ injury. It has also been suggested that in chronic hypertension, Ang II and ET-1 play an important role in the maintenance of hypertension and cardiorenal damage when NO bioactivity is deficient. 46, 57, 92 In chronic hypertensive models, the administration of ACE inhibitors as well as AT 1 blockers reduces the severity of hypertension and ameliorates cardiorenal injury. 92, 93 AT 1 blockers can largely attenuate renal pressor response to NOS inhibition but not to the same degree as the systemic pressor response, suggesting that Ang II may not have a major interaction with NO in the maintenance of total peripheral resistance and therefore systemic blood pressure. However, renal vasoconstriction in response to NOS inhibition is largely mediated by the unbridled influence of endogenous Ang II, especially when Ang II is increased. 24 In summary, it has become clear that the balance between NO and Ang II, rather than the absolute concentration of either, is what determines their effect on cardiovascular and renal physiology and pathophysiology (Figure 1 ). The reasons for the imbalances between the substances are often unclear. An understanding of the relations between hypertension, end-organ damage, and the NO-Ang II axis leads one to believe that available therapeutic strategies capable of restoring the homeostatic balance of these vasoactive agents within the vessel wall would be effective in preventing or arresting end-organ disease.
